Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 IASO Bio's Nanjing Mfg. Facility Licensed for CAR-T Cell Therapies | Contract Pharma

What are you searching for?

Sign in
Breaking News

IASO Bio’s Nanjing Mfg. Facility Licensed for CAR-T Cell Therapies

The cell production workshop designed according to cGMP requirements has the capacity of producing 3,000 batches of CAR-T cell products per year.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

IASO Biotherapeutics, a clinical-stage biopharmaceutical company developing and manufacturing innovative cell therapies and antibody products, was granted a drug manufacturing license by the Medical Products Administration of Province Jiangsu (JSMPA) for its commercial manufacturing facility in Nanjing following a successful comprehensive inspection.
 
The cell production workshop, as a core facility area, is designed in the form of a workstation according to the cGMP requirements and NMPA/EMA/FDA regulations with the capacity of producing 3,000 batches of CAR-T cell products per year. The approval of the drug manufacturing license for IASO Bio’s Nanjing commercial manufacturing facility marks a key step of transition from clinical development to commercialization.
 
Dr. David He, Chief Technology Officer and Executive Vice President of IASO Bio said, The approval of the drug manufacturing license is a milestone before the launch of the new drug. It is of great significance for the launch of the first chimeric antigen receptor (CAR)-T cell therapy drug developed by IASO Bio. It marks that IASO Bio has the full in-house capabilities to manufacture GMP compliant Plasmids, Lentiviral vectors, and CAR-T cell therapy products. We will take it as a new starting point to bring our first CAR-T product for the treatment of Multiple myeloma to the market, and provide patients with safe, effective, and reliable cell immunotherapy as soon as possible, and strive to bring hope to patients.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics